Royalty Pharma PLC (NASDAQ:RPRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Royalty Pharma PLC (NASDAQ:RPRX) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $47.50.

A number of analysts have weighed in on RPRX shares. Morgan Stanley reduced their price target on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Citigroup boosted their target price on Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 target price for the company in a research report on Friday, January 30th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Finally, TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th.

Key Headlines Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Royalty raised its quarterly dividend to $0.235 per share (annualized $0.94, ~2.2% yield), which increases income appeal and reduces dilution concerns for income‑focused holders. Royalty Pharma (RPRX) MarketBeat
• Positive Sentiment: Several analysts maintain bullish views and higher targets (Citigroup raised its target to $50; consensus target ~ $47.50), providing a technical/analyst support level that can limit downside. Royalty Pharma (RPRX) MarketBeat Analyst Notes
• Neutral Sentiment: Royalty is scheduled to report quarterly results this week — a calendar event that can increase short‑term volatility but contains no new operational detail until the release. Royalty Pharma (RPRX) Projected to Post Earnings on Wednesday
• Negative Sentiment: CFO Terrance Coyne executed three large sales Feb 2–4 (total ≈243,541 shares for ≈$10.36M), materially reducing his stake — heavy insider selling at the C‑suite level often triggers investor concern and can exert downward pressure on the stock. SEC Form 4 — Terrance P. Coyne
• Negative Sentiment: Zacks warns Royalty may not have the setup for an earnings beat in the upcoming print, which can cap upside and prompt traders to trim positions ahead of results. Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

Royalty Pharma Stock Up 1.7%

Royalty Pharma stock opened at $43.68 on Thursday. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. Royalty Pharma has a 1-year low of $29.66 and a 1-year high of $43.76. The firm’s fifty day simple moving average is $39.74 and its 200-day simple moving average is $37.89. The company has a market capitalization of $25.21 billion, a P/E ratio of 33.09, a P/E/G ratio of 1.64 and a beta of 0.42.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The firm had revenue of $609.29 million for the quarter, compared to the consensus estimate of $765.01 million. Sell-side analysts forecast that Royalty Pharma will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be given a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a yield of 2.2%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio (DPR) is presently 66.67%.

Insider Transactions at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 20,163 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $43.29, for a total transaction of $872,856.27. Following the completion of the transaction, the chief financial officer owned 22,885 shares of the company’s stock, valued at approximately $990,691.65. The trade was a 46.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,309,216 shares of company stock valued at $52,015,364 over the last 90 days. Corporate insiders own 18.90% of the company’s stock.

Hedge Funds Weigh In On Royalty Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of RPRX. Smartleaf Asset Management LLC boosted its holdings in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares during the period. Private Trust Co. NA lifted its holdings in shares of Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares during the period. Financial Consulate Inc. bought a new position in Royalty Pharma during the third quarter worth about $35,000. Larson Financial Group LLC boosted its holdings in Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares in the last quarter. Finally, Richardson Financial Services Inc. bought a new stake in shares of Royalty Pharma in the 3rd quarter valued at approximately $54,000. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.